Warburg-Cinotti Syndrome: Comprehensive Disease Characteristics Report

Disease Name: Warburg-Cinotti Syndrome (WCS) MONDO ID: MONDO:0032579 OMIM: #618175 Category: Connective Tissue Report compiled: 2026-08-30 (5-iteration autonomous investigation; 11 confirmed findings; 25 papers reviewed)

Summary

Warburg-Cinotti syndrome (WCS; MONDO:0032579; OMIM #618175) is an ultra-rare, autosomal-dominant connective-tissue disorder caused by recurrent activating (gain-of-function) germline missense variants in the collagen receptor tyrosine kinase gene DDR2 (discoidin domain receptor tyrosine kinase 2; OMIM 191311). Only two recurrent hotspot variants have been reported to date — c.1829T>C (p.Leu610Pro) and c.2219A>G (p.Tyr740Cys) — and both render the receptor constitutively autophosphorylated independent of its collagen ligand, bypassing the normal autoinhibitory constraints on kinase activity (PMID: 30449416; PMID: 41259339).

Clinically, WCS is a progressive fibro-proliferative disorder. The classic tetrad comprises progressive corneal neovascularization, keloid formation, chronic skin ulcers with wasting of subcutaneous tissue, finger flexion contractures, and acro-osteolysis (PMID: 30449416). Curated Human Phenotype Ontology annotations (35 features derived from OMIM:618175 via the Monarch Initiative) reveal a much broader, multisystem picture involving craniofacial dysmorphism (narrow nose, long face, posteriorly rotated ears), the ocular surface (corneal neovascularization, symblepharon, limbal stem-cell deficiency), the ear (conductive hearing loss, cholesteatoma), the skin (thin skin, poor wound healing), the skeleton (osteolysis of phalanges, joint contractures), and the respiratory system (pneumothorax). Mechanistically, constitutively active DDR2 in fibroblasts hyperactivates ERK1/2 and NF-κB signaling and drives matrix-metalloproteinase (MMP-1/2/9/13) and MT1-MMP (MMP-14)-mediated extracellular-matrix remodeling, producing the fibrosis, neovascularization, and tissue destruction that characterize the disease (PMID: 28270508; PMID: 25733533).

Because WCS is fundamentally a kinase-activation disease, DDR2-inhibiting tyrosine kinase inhibitors are a mechanistically rational therapeutic strategy. The BCR-ABL inhibitor dasatinib abolishes mutant DDR2 autophosphorylation in patient fibroblasts (PMID: 30449416), and imatinib, nilotinib, and dasatinib are all potent DDR1/DDR2 inhibitors (PMID: 18938156), making them repurposing candidates — although no clinical trial and no gain-of-function animal model of WCS has yet been reported. Notably, DDR2 is allelic to a mechanistically opposite disorder: biallelic loss-of-function DDR2 variants cause the autosomal-recessive skeletal dysplasia SMED-SL (spondylo-meta-epiphyseal dysplasia, short limb–abnormal calcification type; OMIM 271665) (PMID: 24725993; PMID: 36720430).

Section 1 — Disease Information

Overview. Warburg-Cinotti syndrome is a progressive connective-tissue disorder defined by simultaneous fibro-proliferation (keloids, corneal pannus/neovascularization) and tissue destruction (chronic skin ulcers, subcutaneous wasting, acro-osteolysis). It is caused by gain-of-function activation of a collagen-sensing receptor tyrosine kinase, positioning it at the intersection of extracellular-matrix biology and kinase-signaling disease.

Key identifiers (verified via EBI OLS4 MONDO ontology query; Finding F010):

Synonyms / alternative names: Warburg-Cinotti syndrome; abbreviation WRCN (MONDO synonym).

Information source type. Given fewer than ~10 reported individuals worldwide, all information is derived from aggregated disease-level resources (OMIM, MONDO, HPO/Monarch) and individual case reports/case series — not from large EHR or registry datasets. The foundational cohort is 6 affected individuals from 4 families (PMID: 30449416).

Section 2 — Etiology

Primary cause (genetic). WCS is a monogenic, autosomal-dominant disorder caused by heterozygous activating missense variants in DDR2. Two recurrent variants account for all molecularly confirmed classic cases: p.Leu610Pro and p.Tyr740Cys (PMID: 30449416). A novel maternally inherited variant was reported in a neonatal case (PMID: 41778429), indicating the mutational spectrum may be broader than the two original hotspots.

Genetic risk factors. The causal variants are themselves the risk determinant; there are no reported susceptibility loci or modifier genes. Both de novo and inherited transmission are documented — a proven de novo variant arose in a mother who then transmitted it to two children (PMID: 30449416).

Environmental risk factors. No environmental cause is required for disease. However, local trauma appears to provoke and accelerate lesions: a 7-year-old developed a gelatinous vascularized conjunctival mass after ocular trauma that recurrently regrew and invaded the entire cornea despite repeated surgery (PMID: 39095787). This mirrors the keloid biology of WCS, in which the skin overreacts to injury.

Protective factors. None identified (genetic or environmental). Given the trauma-provocation pattern, avoidance of unnecessary trauma/surgery to affected surfaces may be practically protective, though this is inferential.

Gene-environment interaction. The plausible model is that a constitutively active DDR2 receptor lowers the threshold for a pathological wound-healing/ECM-remodeling response, so that ordinary mechanical injury triggers exaggerated, self-perpetuating fibro-proliferation and neovascularization.

Section 3 — Phenotypes

WCS is a multisystem disorder. The classic clinical tetrad/pentad (PMID: 30449416; PMID: 41259339):

• Progressive corneal neovascularization (HP:0011496) — ocular surface; progressive; trauma-provoked
• Keloid formation — skin; progressive fibro-proliferation
• Chronic skin ulcers / poor wound healing (HP:0001058) — skin; chronic
• Wasting of subcutaneous tissue — skin/subcutis; progressive
• Flexion contractures of the fingers (HP:0012785) — musculoskeletal; progressive
• Acro-osteolysis / osteolytic phalangeal defects (HP:0009771) — skeletal; progressive

Curated HPO spectrum with frequencies (Monarch/HPOA, 35 annotations derived from OMIM:618175; Finding F011):

Onset, severity, progression. Onset spans childhood to adulthood, with a documented neonatal presentation (respiratory distress from choanal abnormalities) at the earliest extreme (PMID: 41778429; PMID: 39095787). Most core features are progressive, and expressivity is variable even within families.

Quality-of-life impact. No formal EQ-5D/SF-36 data exist. Inferred impact is substantial: progressive corneal opacification/neovascularization threatens vision (visual impairment in 75%), finger contractures and acro-osteolysis impair hand function and dexterity, chronic non-healing ulcers cause pain and infection risk, and conductive hearing loss/cholesteatoma affect hearing.

Section 4 — Genetic / Molecular Information

Causal gene. DDR2 — discoidin domain receptor tyrosine kinase 2; HGNC:2731; NCBI Gene ID 4921; OMIM 191311; chromosome 1q23.3. DDR2 is a non-integrin, collagen-activated receptor tyrosine kinase.

Pathogenic variants (WCS, gain of function):

Classification. The two recurrent variants are pathogenic (recurrent, functionally validated, segregating; consistent with ACMG PS1/PS3/PM1/PP1 lines of evidence). Allele frequency in population databases is effectively absent (private, disease-causing).

Functional consequence — gain of function. Patient fibroblasts show increased DDR2 phosphorylation, indicating reduced autoinhibition and ligand-independent activation (PMID: 30449416). Biochemical work shows both variants exhibit ligand-independent constitutive autophosphorylation as full-length proteins, and the p.Tyr740Cys kinase has enhanced autophosphorylation and substrate-phosphorylation rates with unchanged ATP affinity — the unphosphorylated mutant behaves kinetically like fully phosphorylated wild type, i.e., it bypasses autoinhibitory constraints (PMID: 41259339).

Allelic contrast (loss of function → distinct disorder). Biallelic loss-of-function DDR2 variants (missense, nonsense, deletion, splice; e.g., p.S823Cfs2) cause SMED-SL (spondylo-meta-epiphyseal dysplasia, short limb–abnormal calcification type; OMIM 271665), an autosomal-recessive skeletal dysplasia, via defective intracellular trafficking and loss of collagen-induced activation (PMID: 24725993; PMID: 36720430). This is the opposite functional mechanism* to WCS.

Modifier genes / epigenetics / chromosomal abnormalities. None reported. WCS is not associated with aneuploidy, translocations, or copy-number variants; no epigenetic signature has been described.

Section 5 — Environmental Information

No toxin, radiation, pollution, occupational, infectious, or lifestyle cause is implicated in WCS — it is a monogenic disorder. The one clear environmental modifier is mechanical/surgical trauma, which provokes and accelerates ocular and cutaneous lesions and drives post-surgical recurrence (PMID: 39095787). No infectious agents cause or trigger the disease.

Section 6 — Mechanism / Pathophysiology

Causal chain (upstream → downstream):

Germline activating DDR2 missense variant (p.Leu610Pro / p.Tyr740Cys)
        │  (reduced autoinhibition; bypass of autoinhibitory constraints)
        ▼
Ligand-INDEPENDENT constitutive DDR2 kinase autophosphorylation
        │  (does not require collagen binding)
        ▼
Sustained downstream signaling in fibroblasts: ERK1/2  +  NF-κB
        │
        ▼
Up-regulation of MMPs (MMP-1/2/9/13) and MT1-MMP (MMP-14)
   + DDR2 tethers active MT1-MMP to collagen fibers (sustained ECM degradation)
        │
        ▼
Dysregulated ECM remodeling → fibro-proliferation (keloids, corneal pannus/
neovascularization) AND tissue destruction (ulcers, subcutaneous wasting, acro-osteolysis)
        │
        ▼
Progressive multisystem clinical phenotype

Molecular pathways. DDR2 is a collagen-activated RTK that up-regulates matrix metalloproteinases. In murine melanoma cells, DDR2 drives MMP-2/9 expression through the ERK/NF-κB pathway — DDR2 siRNA suppresses ERK1/2 and NF-κB and down-regulates MMP-2/9 (PMID: 25733533). Relevant GO/pathway terms: transmembrane receptor protein tyrosine kinase signaling (GO:0007169), positive regulation of ERK1/ERK2 cascade (GO:0070374), extracellular matrix disassembly (GO:0022617), collagen catabolic process (GO:0030574).

Cellular processes / effector cell. The fibroblast (CL:0000057) is the central effector cell. In human fibroblasts, DDR2 mediates collagen-induced up-regulation of MT1-MMP and pro-MMP-2 activation (PMID: 28270508). DDR2 also tethers active MT1-MMP to collagen fibers within "DDR2-containing remnants," sustaining pericellular ECM degradation (PMID: 33882324). DDR2 additionally governs fibroblast proliferation as an ECM sensor (PMID: 11375938).

Protein dysfunction. The mutations act by gain of function at the kinase, not by misfolding/aggregation. p.Tyr740Cys increases catalytic activity and removes the autoinhibitory clamp; unphosphorylated mutant behaves like phosphorylated wild type (PMID: 41259339).

Tissue-damage / fibrosis mechanism. DDRs are established anti-fibrotic targets across liver, kidney, lung, cardiovascular, and skin (hypertrophic scar) fibrosis (PMID: 40796038; PMID: 24725424). DDR dysregulation after injury is detrimental and promotes inflammation and fibrosis (PMID: 24361528). In WCS, constitutive DDR2 activity produces a chronic, injury-independent version of this fibrotic program.

Immune involvement. Not a primary autoimmune or immunodeficiency disorder, though NF-κB activation and secondary infection of chronic ulcers/skin fusion contribute to morbidity.

Molecular profiling. No transcriptomic, proteomic, metabolomic, or single-cell datasets specific to WCS patients are available; mechanistic inferences derive from DDR2 fibroblast and cancer-cell models.

Section 7 — Anatomical Structures Affected

Organ / system level:

Tissue and cell level. Predominantly connective tissue and the corneal/ocular-surface epithelium/stroma. The key targeted cell is the fibroblast (CL:0000057); corneal limbal stem-cell deficiency (HP:0032107) implicates limbal epithelial stem cells.

Subcellular level. Disease originates at the plasma membrane (GO:0005886) receptor; downstream effects converge on the extracellular matrix / extracellular region (GO:0005576) and involve collagen-containing ECM (GO:0062023).

Localization / lateralization. Ocular and cutaneous lesions are typically bilateral but can be asymmetric, with lesion location influenced by sites of trauma.

Section 8 — Temporal Development

• Onset: Ranges from neonatal (PMID: 41778429) through childhood (PMID: 39095787) to adulthood; onset pattern is generally chronic/insidious and progressive.
• Progression: Progressive for most features (corneal neovascularization, acro-osteolysis, contractures, skin lesions). Ocular disease can be stepwise/accelerated by trauma and surgery, with rapid regrowth after intervention (PMID: 39095787).
• Course / duration: Chronic, lifelong. No spontaneous remission is described.
• Critical periods: Peri-traumatic and peri-surgical windows are periods of vulnerability (lesion provocation/recurrence) and represent the logical window for mechanism-based (kinase-inhibitor) intervention to blunt the fibro-proliferative response.

Section 9 — Inheritance and Population

Epidemiology. WCS is ultra-rare: only 6 affected individuals from 4 families were reported at initial description (PMID: 30449416); by 2024 the literature still described ~6 cases worldwide ("Only six cases have been reported worldwide and our knowledge of this disease remained sparse") (PMID: 39095787), with additional single cases since (PMID: 41778429). No prevalence/incidence figures are calculable; there is no Orphanet epidemiology entry.

Inheritance genetics:

• Pattern: Autosomal dominant (AD).
• New vs inherited: Both de novo and inherited — a de novo variant in a mother was transmitted to two children (PMID: 30449416).
• Penetrance: Appears high in reported carriers, but cohort too small to quantify.
• Expressivity: Variable, even intrafamilially.
• Anticipation / mosaicism / founder effects / consanguinity / carrier frequency: No evidence for anticipation; no founder effect (variants are private/recurrent hotspots, not population-restricted); consanguinity is not relevant (dominant, not recessive — in contrast to the allelic recessive SMED-SL). Carrier frequency not applicable for a dominant de-novo-capable disorder.

Demographics. No ethnic predilection, sex bias, or geographic clustering has been established given the tiny case count.

Section 10 — Diagnostics

Genetic testing is definitive. Diagnosis rests on identifying a heterozygous activating DDR2 missense variant (p.Leu610Pro or p.Tyr740Cys, or a novel spectrum variant).

• WES/WGS: High utility — the original cohort and the neonatal case were solved by whole-exome sequencing (PMID: 30449416; PMID: 41778429).
• Single-gene / panel testing: Targeted DDR2 sequencing (or a connective-tissue/skeletal-dysplasia panel including DDR2) is appropriate once WCS is suspected clinically.
• CMA / karyotype / FISH / mtDNA / repeat-expansion testing: Not indicated (no structural, mitochondrial, or repeat-expansion mechanism).

Functional / laboratory confirmation. Patient-derived fibroblasts show increased DDR2 autophosphorylation, which can serve as a functional assay (PMID: 30449416).

Imaging. Hand radiographs demonstrate acro-osteolysis and phalangeal osteolytic defects; ophthalmic examination/slit-lamp documents corneal neovascularization, pannus, symblepharon, and corneal thinning; CT may characterize cholesteatoma/EAC atresia and choanal abnormalities.

Biopsy/pathology. Skin lesions show keloidal fibro-proliferation; ocular masses show vascularized fibrovascular tissue invading the cornea (PMID: 39095787).

Differential diagnosis. Multicentric osteolysis/nodulosis/arthropathy (MONA, MMP2), other acro-osteolysis syndromes (Hajdu-Cheney), scleroderma/fibrosing disorders, and — at the gene level — the allelic recessive SMED-SL (opposite mechanism, skeletal dysplasia phenotype) (PMID: 36720430).

Screening. No population/newborn screening exists or is warranted given rarity. Cascade genetic testing of at-risk relatives in a known family is appropriate.

Section 11 — Outcome / Prognosis

No survival, mortality, or formal QoL data exist for this ultra-rare disorder. The disease is chronic, progressive, and lifelong, with cumulative morbidity from:

• Vision loss — progressive corneal neovascularization/opacification (visual impairment in 75%), aggravated by recurrence after ocular surgery (PMID: 39095787).
• Hand disability — flexion contractures and acro-osteolysis.
• Chronic wounds/infection — non-healing ulcers, skin fusion, sterile/infected abscesses.
• Hearing loss — conductive impairment, cholesteatoma.
• Respiratory events — pneumothorax (33%); neonatal respiratory distress from choanal abnormalities.

Prognostic factors are not formally established; degree of DDR2 hyperactivation and trauma burden are plausible drivers of severity. Recovery potential is limited under current supportive-only management, but is the central rationale for mechanism-based therapy.

Section 12 — Treatment

There is no approved, disease-specific therapy; management is currently supportive (wound care, ophthalmic surface management, contracture/hand therapy, hearing rehabilitation, treatment of infection). Surgery on ocular/skin lesions is complicated by trauma-provoked recurrence (PMID: 39095787), so surgical decisions should be cautious.

Mechanism-based (experimental) pharmacotherapy — DDR2 tyrosine-kinase inhibition:

Key supporting quote: "we found that the protein kinase inhibitor dasatinib prevented DDR2 autophosphorylation in fibroblasts, suggesting an approach to treatment" (PMID: 30449416); and "all 3 compounds are potent inhibitors of the kinase activity of both DDR1 and DDR2" (PMID: 18938156).

Personalized-medicine rationale. Because WCS is driven by a single, well-defined activated kinase with no evidence of other growth-pathway activation (PMID: 30449416), it is a strong candidate for genotype-guided kinase-inhibitor therapy. No gene therapy, cell therapy, RNA therapy, or immunotherapy has been reported. No completed or registered clinical trial (NCT) specific to WCS was identified.

Section 13 — Prevention

• Primary prevention: Not applicable to a de-novo-capable germline disorder. Genetic counseling and cascade/prenatal or preimplantation genetic testing are options for known-variant families.
• Secondary prevention: Early molecular diagnosis (WES) and early ophthalmic/skin surveillance to intervene before irreversible damage.
• Tertiary prevention: Minimize provocative trauma/surgery to affected surfaces, aggressive wound-infection control, contracture-preventive physiotherapy, hearing/vision rehabilitation. Mechanism-based TKI therapy — if validated — would be a tertiary-preventive strategy to halt progression.
• Immunization / public health / environmental interventions: Not applicable.

Section 14 — Other Species / Natural Disease

• Orthologous gene: DDR2 is conserved. Mouse Ddr2 — NCBI Gene ID 18214 (Mus musculus, NCBI Taxon 10090); zebrafish DDR2 orthologs (Danio rerio, NCBI Taxon 7955).
• Natural disease: No naturally occurring WCS-equivalent (gain-of-function DDR2) disease has been described in companion animals or wildlife (no OMIA entry identified). Available animal data are engineered loss-of-function models (below), which model DDR2 deficiency, not WCS.
• Comparative biology: DDR2's role in chondrocyte proliferation, skin wound healing, and craniofacial/palate development is evolutionarily conserved from zebrafish to mouse to human (PMID: 11375938; PMID: 42323896).
• Transmission / zoonosis: Not applicable (genetic disorder).

Section 15 — Model Organisms

Important caveat: All existing animal models are loss-of-function (Ddr2-null / knockdown), which model the allelic recessive SMED-SL rather than gain-of-function WCS. No gain-of-function (knock-in p.Leu610Pro/p.Tyr740Cys) animal model has yet been reported (Findings F002/F007).

Model databases: MGI (mouse Ddr2), ZFIN (zebrafish ddr2), Alliance of Genome Resources.

Supporting quotes: "These mice exhibit dwarfism and shortening of long bones... caused by reduced chondrocyte proliferation" and "In a skin wound healing model, DDR2-/- mice exhibit a reduced proliferative response" (PMID: 11375938); "Knock-down and knock-out of DDR2-orthologs in zebrafish caused craniofacial abnormalities resembling CPO in humans" (PMID: 42323896).

Mechanistic Model / Interpretation

WCS is best understood as a "constitutive kinase" connective-tissue disease. A single-nucleotide germline change removes the autoinhibitory brake on DDR2, so the receptor signals continuously without needing to bind collagen. In fibroblasts — the disease's effector cell — this locks in a chronic ERK/NF-κB → MMP/MT1-MMP program that simultaneously builds abnormal matrix (keloids, corneal pannus and neovascularization) and destroys existing tissue (chronic ulcers, subcutaneous wasting, acro-osteolysis). The apparent paradox of "too much scarring and too much destruction" is resolved by recognizing that both are outputs of dysregulated ECM remodeling driven by the same overactive receptor.

Two natural experiments frame the mechanism:

                DDR2 dosage/activity axis
LOSS of function  ◄──────────────────────────────►  GAIN of function
   SMED-SL (AR)        normal DDR2          Warburg-Cinotti (AD)
 skeletal dysplasia,   collagen-cued        constitutive kinase,
 short limbs,          ECM sensing          fibrosis + osteolysis +
 abnormal calcif.      & wound healing      neovascularization
 (trafficking defect,  (chondrocyte prolif, (ligand-independent
 loss of ligand        wound repair)         autophosphorylation)
 activation)

Both ends of this axis are pathological, and both are informative: the LOF mouse/zebrafish models reveal DDR2's normal developmental roles (chondrocyte proliferation, wound healing, palate formation) — roles that manifest as skeletal/craniofacial overlap features in WCS — while the GOF human disease shows what happens when the same receptor is unleashed.

The therapeutic corollary is unusually clean: turn the kinase off. Dasatinib already abolishes mutant DDR2 autophosphorylation in patient cells, and multiple approved TKIs plus selective allosteric DDR2 inhibitors are available for testing.

Evidence Base

Limitations and Knowledge Gaps

1. Extreme rarity. With fewer than ~10 reported individuals, no epidemiology (prevalence/incidence), penetrance, expressivity, survival, or QoL statistics can be calculated. Phenotype frequencies from HPOA rest on a very small denominator.
2. No gain-of-function animal model. Every available in-vivo model is LOF (Ddr2-null mouse, ddr2-knockdown zebrafish), which recapitulates SMED-SL, not WCS. A knock-in GOF model is the single biggest missing tool.
3. No WCS-specific omics. No transcriptomic, proteomic, metabolomic, single-cell, or spatial data exist for patient tissues; mechanistic inference relies on DDR2 cancer/fibroblast surrogates.
4. Therapy is unproven in humans. Dasatinib/imatinib/nilotinib efficacy is demonstrated at the level of kinase inhibition and patient-cell autophosphorylation only — no clinical trial (NCT) has tested any DDR2 inhibitor in WCS, and TKI toxicity in a chronic, pediatric-onset setting is a serious concern.
5. Genotype–phenotype spectrum unclear. Whether the novel neonatal variant behaves identically to the two hotspots, and what determines variable expressivity, is unknown.
6. Ontology mapping incomplete. No Orphanet, ICD, or MeSH code exists, complicating registry-based case finding.

Proposed Follow-up Experiments / Actions

1. Generate a knock-in GOF model. Create Ddr2^L610P^ and Ddr2^Y740C^ knock-in mice (and/or zebrafish) to test whether they recapitulate corneal neovascularization, keloids, and acro-osteolysis, and to serve as a preclinical drug-testing platform.
2. Preclinical TKI dose-response. Systematically compare dasatinib, imatinib, nilotinib, and selective allosteric inhibitors (e.g., WRG-28) in patient fibroblasts and the new GOF model for suppression of autophosphorylation, ERK/NF-κB, and MMP/MT1-MMP output, with careful attention to therapeutic index.
3. N-of-1 / basket clinical evaluation. Given mechanistic clarity and drug availability, pursue carefully monitored compassionate-use or n-of-1 trials of a DDR2 inhibitor (with local/topical formulation considered for the ocular surface to limit systemic toxicity), registering an NCT.
4. Patient-tissue multi-omics. Perform single-cell/spatial transcriptomics and proteomics on WCS keloid, ulcer margin, and corneal pannus tissue to map fibroblast subpopulations and confirm the ERK/NF-κB/MMP program in situ.
5. International registry & GeneMatcher outreach. Aggregate all known cases to define natural history, penetrance, expressivity, and genotype–phenotype correlations; seek an Orphanet/ICD-11 code.
6. Biomarker development. Validate DDR2 phosphorylation and circulating MMP-2/9/13 as pharmacodynamic biomarkers for future trials.

Evidence-source key: human clinical (case reports/cohorts) — PMIDs 30449416, 39095787, 41778429, 35036505; in vitro / biochemical — 41259339, 28270508, 25733533, 33882324, 18938156, 41955962; model organism — 11375938, 42323896; review/synthesis — 40796038, 24725424, 24361528; allelic disorder — 24725993, 36720430; ontology cross-references verified via EBI OLS4 (MONDO) and Monarch/HPOA.